We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
- Authors
Kater, A. P.; Harrup, R.; Kipps, T. J.; Eichhorst, B.; Owen, C. J.; Assouline, S.; Lamanna, N.; Robak, T.; Serna, J. d. l.; Jaeger, U.; Cartron, G.; Montillo, M.; Mellink, C.; Chyla, B.; Thadani‐Mulero, M.; Lefebure, M.; Jiang, Y.; Millen, R.; Boyer, M.; Seymour, J. F.
- Abstract
B Introduction: b Fixed-duration (FD) VenR treatment (tx) in patients (pts) with I R i / I R i CLL in the Phase 3 MURANO trial (NCT02005471) resulted in superior progression-free survival (PFS) and overall survival (OS), versus bendamustine (B)R. MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
- Subjects
CHRONIC lymphocytic leukemia; BREAST cancer research; CLINICAL trials
- Publication
Hematological Oncology, 2023, Vol 41, p239
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_156